129 related articles for article (PubMed ID: 21752640)
1. Bioactive sulfoximines: syntheses and properties of Vioxx analogs.
Park SJ; Buschmann H; Bolm C
Bioorg Med Chem Lett; 2011 Aug; 21(16):4888-90. PubMed ID: 21752640
[TBL] [Abstract][Full Text] [Related]
2. Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
Caturla F; Amat M; Reinoso RF; Córdoba M; Warrellow G
Bioorg Med Chem Lett; 2006 Jun; 16(12):3209-12. PubMed ID: 16616494
[TBL] [Abstract][Full Text] [Related]
3. Rofecoxib analogues possessing a nitric oxide donor sulfohydroxamic acid (SO2NHOH) cyclooxygenase-2 pharmacophore: synthesis, molecular modeling, and biological evaluation as anti-inflammatory agents.
Bhardwaj A; Huang Z; Kaur J; Knaus EE
ChemMedChem; 2012 Jan; 7(1):62-7. PubMed ID: 21990143
[No Abstract] [Full Text] [Related]
4. Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
Caturla F; Amat M; Reinoso RF; Calaf E; Warrellow G
Bioorg Med Chem Lett; 2006 Jul; 16(13):3605-8. PubMed ID: 16647258
[TBL] [Abstract][Full Text] [Related]
5. Reply to the Vioxx debacle.
Knudsen JF; Sokol GH
Am J Med; 2006 Jan; 119(1):93-4. PubMed ID: 16431207
[No Abstract] [Full Text] [Related]
6. Nitrooxymethyl-substituted analogues of rofecoxib: synthesis and pharmacological characterization.
Boschi D; Cena C; Di Stilo A; Rolando B; Manzini P; Fruttero R; Gasco A
Chem Biodivers; 2010 May; 7(5):1173-82. PubMed ID: 20491074
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
Navidpour L; Amini M; Shafaroodi H; Abdi K; Ghahremani MH; Dehpour AR; Shafiee A
Bioorg Med Chem Lett; 2006 Sep; 16(17):4483-7. PubMed ID: 16806914
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: Replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity.
Zarghi A; Praveen Rao PN; Knaus EE
Bioorg Med Chem; 2007 Jan; 15(2):1056-61. PubMed ID: 17067801
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of rofecoxib bound to human cyclooxygenase-2.
Orlando BJ; Malkowski MG
Acta Crystallogr F Struct Biol Commun; 2016 Oct; 72(Pt 10):772-776. PubMed ID: 27710942
[TBL] [Abstract][Full Text] [Related]
10. 5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethers.
Sakya SM; Cheng H; Lundy Demello KM; Shavnya A; Minich ML; Rast B; Dutra J; Li C; Rafka RJ; Koss DA; Li J; Jaynes BH; Ziegler CB; Mann DW; Petras CF; Seibel SB; Silvia AM; George DM; Hickman A; Haven ML; Lynch MP
Bioorg Med Chem Lett; 2006 Mar; 16(5):1202-6. PubMed ID: 16380252
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.
Tietz O; Dzandzi J; Bhardwaj A; Valliant JF; Wuest F
Bioorg Med Chem Lett; 2016 Mar; 26(6):1516-1520. PubMed ID: 26898334
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R
Bioorg Med Chem; 2010 Aug; 18(16):5855-60. PubMed ID: 20650641
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors.
Fioravanti R; Bolasco A; Manna F; Rossi F; Orallo F; Ortuso F; Alcaro S; Cirilli R
Eur J Med Chem; 2010 Dec; 45(12):6135-8. PubMed ID: 20974503
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.
Harrak Y; Casula G; Basset J; Rosell G; Plescia S; Raffa D; Cusimano MG; Pouplana R; Pujol MD
J Med Chem; 2010 Sep; 53(18):6560-71. PubMed ID: 20804197
[TBL] [Abstract][Full Text] [Related]
15. One-Step Transformation from Rofecoxib to a COX-2 NIR Probe for Human Cancer Tissue/Organoid Targeted Bioimaging.
Xie L; Li R; Zheng B; Xie Z; Fang X; Dai T; Wang X; Li L; Wang L; Cuny GD; Eriksen J; Tu D; Chen Z; Wang X; Chen X; Hu M
ACS Appl Bio Mater; 2021 Mar; 4(3):2723-2731. PubMed ID: 35014311
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the methanesulfonyl pharmacophore by a N-acetylsulfonamido bioisostere.
Zarghi A; Rao PN; Knaus EE
J Pharm Pharm Sci; 2007; 10(2):159-67. PubMed ID: 17706175
[TBL] [Abstract][Full Text] [Related]
17. Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.
Tsai WJ; Shiao YJ; Lin SJ; Chiou WF; Lin LC; Yang TH; Teng CM; Wu TS; Yang LM
Bioorg Med Chem Lett; 2006 Sep; 16(17):4440-3. PubMed ID: 16814546
[TBL] [Abstract][Full Text] [Related]
18. 2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols.
Singh P; Mittal A; Kaur S; Kumar S
Eur J Med Chem; 2008 Dec; 43(12):2792-9. PubMed ID: 18262309
[TBL] [Abstract][Full Text] [Related]
19. Effect of Vioxx on adipose tissue development in mice with genetically determined obesity.
Lijnen HR
Thromb Haemost; 2008 Nov; 100(5):954. PubMed ID: 18989545
[No Abstract] [Full Text] [Related]
20. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA
Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
